[1]赵军,师建平.蒙药蓝刺头对去卵巢骨质疏松大鼠TGF-β1、UI、BMD的作用[J].西部中医药,2022,35(07):16-19.[doi:10.12174/j.issn.2096-9600.2022.07.04]
 ZHAO Jun,SHI Jianping.Influence of Mongolian Medicine Lancitou on TGF-β1, UI and BMD of Ovariectomized Rats with Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2022,35(07):16-19.[doi:10.12174/j.issn.2096-9600.2022.07.04]
点击复制

蒙药蓝刺头对去卵巢骨质疏松大鼠TGF-β1、UI、BMD的作用
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年07期
页码:
16-19
栏目:
药理研究
出版日期:
2022-07-15

文章信息/Info

Title:
Influence of Mongolian Medicine Lancitou on TGF-β1, UI and BMD of Ovariectomized Rats with Osteoporosis
作者:
赵军1 师建平2
1.内蒙古自治区中医医院,内蒙古 呼和浩特 010020
2.内蒙古医科大学中医学院
Author(s):
ZHAO Jun1 SHI Jianping2
1.Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohehot 010020, China
2.College of TCM, Inner Mongolia Medical University
关键词:
骨质疏松症绝经后白细胞介素1转化生长因子子宫指数蒙药蓝刺头
Keywords:
postmenopausal osteoporosisIL-1TGF-UIMongolian medicine
分类号:
R592
DOI:
10.12174/j.issn.2096-9600.2022.07.04
文献标志码:
A
摘要:
目的观察蒙药蓝刺头对去卵巢骨质疏松(osteoporosis,OP)模型大鼠血清白细胞介素1(interleukin-1,IL-1)、股骨头转化生长因子β1(transforming growth factor-β1,TGF-β1)、骨密度(bone mineral density,BMD)、子宫指数(uterus index,UI)的调节作用。 方法制备去卵巢OP大鼠模型,90天后应用蒙药蓝刺头高、中、低浓度及强骨胶囊、己烯雌酚分别灌胃,采血检测血清IL-1,免疫组化染色检测大鼠左侧股骨头TGF-β1;显微CT分析大鼠右侧股骨BMD;计算子宫指数。 结果大鼠去势后子宫缩小,内膜层变薄,腺体上皮、内膜上皮变薄,腺腔直径缩小。1)与假手术组比较,模型组IL-1表达增高,左股骨头TGF-β1、右股骨近端干骺端BMD降低(P<0.01);与模型组比较,蒙药蓝刺头中剂量组、己烯雌酚组、强骨胶囊组血清IL-1表达降低,左股骨头TGF-β1、右股骨近端干骺端BMD增高(P<0.05)。2)UI模型组与假手术组比较差异显著(P<0.01),模型组与蒙药蓝刺头低剂量组比较差异无统计学意义(P>0.05);假手术组与蒙药蓝刺头高、中剂量组及强骨胶囊组、己烯雌酚组比较差异无统计学意义(P>0.05);蒙药蓝刺头与强骨胶囊及己烯雌酚各指标比较差异无统计学意义(P>0.05)。 结论一定剂量蒙药蓝刺头能有效防治PMOP,缓解去势所致副作用,可为运用蒙医“补暖补精-清镇赫依-固骨质壮骨”理论防治PMOP提供实验依据。
Abstract:
ObjectiveTo observe the regulatory effects of Mongolian medicine Lancitou on IL-1, TGF-β1, BMD and UI in ovariectomized rat models with OP. MethodsAfter establishing ovariectomized models with postmenopausal osteoporosis (PMOP), they were drenched with high, moderate and low doses of Mongolian medicine Lancitou, Qianggu capsules and diethylstilbestrol (DES) for 90 days respectively, to detect the level of IL-1 after drawing blood, to measure the expressions of TGF-β1 in left femoral head by using immumohistoche-mical staining; to analyze BMD in right femoral head by using micro-CT; to calculate UI. ResultsAfter castration, the uterus shrank, endometrium, glandular epithelium and intimal epithelium become thinner, lumens diameter reduced. 1)Compared with sham operation group, the expressions of IL-1 in the model group increased, the expressions of TGF-β1 in left femoral head and BMD in proximal epiphysis of the right femur reduced (P<0.01); compared with the model group, the expressions of IL-1 lowered in moderate dose groups of Mongolian medicine Lancitou, DES group and Qianggu capsules group, TGF-β1 in left femoral head and BMD in proximal epiphysis of the right femur increased (P<0.05). 2)The difference was statistically significant when UI model group was compared with sham operation group (P<0.01), the difference had no statistical meaning when the model group was compared with low dose of Mongolian medicine Lancitou (P>0.05); the difference had no statistical meaning when sham operation group was compared with high, moderate dose groups of Mongolian medicine Lancitou, Qianggu capsules group and DES group (P>0.05); the difference had no statistical meaning in the indexes of Mongolian medicine Lancitou, Qianggu capsules and DES (P>0.05). ConclusionSome dose of Mongolian medicine Lancitou could effectively prevent and treat PMOP, alleviate the adverse reaction induced by castration, it could provide experimental reference for the prevention and treatment of PMOP by using the theory “warming and supplementing essence-clearing and calming Heyi-consolidating and strengthening bone” in Mongolian medicine.

相似文献/References:

[1]张德宏,李晶.老年骨质疏松症的病因病机及防治原则探析[J].西部中医药,2013,26(03):90.
 ZHANG Dehong,LI Jing.The Etiology, Pathogenesis and Prevention Principles of Senile Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2013,26(07):90.
[2]张彩凤,程卫东△,王彩霞,等.玫参胶囊治疗围绝经期骨质疏松症60例[J].西部中医药,2012,25(05):16.
 ZHANG Cai-feng,CHENG Wei-dong,WANG Cai-xia,et al.MeiShen Capsule in Treating 60 Cases of Menopausal Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2012,25(07):16.
[3]李晶,宋敏△,罗晓,等.淫羊藿总黄酮对去势大鼠股骨骨组织形态学及生物力学的影响*[J].西部中医药,2014,27(07):13.
 LI Jing,SONG Min,LUO Xiao,et al.Effects of Total Flavonoids of Epimedium on Biodynamics and Bone Morphological Metrology of Ovariectomized Rats[J].Western Journal of Traditional Chinese Medicine,2014,27(07):13.
[4]谢栋,陈大军,马国亮,等.原发性骨质疏松症的骨密度与中医脏腑辨证的相关性研究*[J].西部中医药,2015,28(02):82.
[5]梁敏.绝经后骨质疏松症42例护理体会[J].西部中医药,2015,28(12):129.
[6]李非,李红专,叶丙霖.原发性骨质疏松症的中医药研究现状[J].西部中医药,2016,29(03):136.
 LI Fei,LI Hongzhuan,YE Binlin.Research Status of Primary Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2016,29(07):136.
[7]薄云,夏冰杰,赵丽艳,等.疏肝滋肾汤治疗绝经后女性骨关节炎的临床观察[J].西部中医药,2016,29(07):93.
 BO Yun,XIA Bingjie,ZHAO Liyan,et al.Clinical Observation on ShuGan ZiShen Tang in Osteoarthritis of the Female Patients after the Menopause[J].Western Journal of Traditional Chinese Medicine,2016,29(07):93.
[8]董林,雷宁波,邢涛,等.损伤胶囊对绝经后骨质疏松症患者疼痛、骨密度及骨代谢生化指标的影响[J].西部中医药,2017,30(11):8.
 DONG Lin,LEI Ningbo,XING Tao,et al.The Effects of Damage Capsules on the Pain, Bone Mineral Density and Biochemical Markers of Bone Metabolism of Postmenopausal Osteoporosis Patients[J].Western Journal of Traditional Chinese Medicine,2017,30(07):8.
[9]马风英.仙灵骨葆胶囊联合甲氨蝶呤治疗类风湿性关节炎继发骨质疏松症37例[J].西部中医药,2018,31(02):98.
 MA Fengying.XianLing GuBao Capsules Combined with Methotrexate in Treating 37 Rheumatiod Arthritis Patients with Secondary Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2018,31(07):98.
[10]叶丙霖,李盛华,王想福,等.补肾活血类中药治疗绝经期骨质疏松症的研究进展[J].西部中医药,2018,31(03):136.
 YE Binglin,LI Shenghua,WANG Xiangfu,et al.Study on Kidney-tonifying Blood-activating Herb in Treating Menopausal Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2018,31(07):136.
[11]张长彪,彭冉东,赵军,等.益肾地黄汤联合利塞膦酸钠治疗肾阳虚型绝经后骨质疏松症45例[J].西部中医药,2017,30(04):1.
 ZHANG Changbiao,PENG Randong,ZHAO Jun,et al.YiShen Dihuang Tang Combined with Risedronate Sodium in the Treatment for 45 Cases of Postmenopausal Osteoporosis of Kidney Yang Deficiency Type[J].Western Journal of Traditional Chinese Medicine,2017,30(07):1.
[12]王想福,陈伟国,叶丙霖,等.从“肝肾同源”理论论治绝经后妇女骨质疏松症的研究进展[J].西部中医药,2019,32(06):155.
 WANG Xiangfu,CHEN Weiguo,YE Binglin,et al.Research Progress of Treatment for Osteoporosis of Postmenopausal Women Based on the Theory of ''Same Source of Liver and Kidney ''[J].Western Journal of Traditional Chinese Medicine,2019,32(07):155.
[13]赵军,邓强,彭冉东,等.综合干预方案调治绝经后骨质疏松症患者血瘀质的临床研究[J].西部中医药,2019,32(07):9.
 ZHAO Jun,DENG Qiang,PENG Randong,et al.Clinical Study on Treating Postmenopausal Osteoporosis of Blood Stagnation Constitution with Comprehensive Intervention Regimen[J].Western Journal of Traditional Chinese Medicine,2019,32(07):9.
[14]熊巍,王贵梅.抗骨质疏松胶囊对绝经后骨质疏松症患者骨密度及骨代谢生化指标的影响[J].西部中医药,2022,35(03):104.[doi:10.12174/j.issn.2096-9600.2022.03.23]
 XIONG Wei,WANG Guimei.Influence of Anti-osteoporosis Capsules on Bone Mineral Density and Bone Metabolism Biochemical Markers in Patients with Postmenopausal Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2022,35(07):104.[doi:10.12174/j.issn.2096-9600.2022.03.23]

备注/Memo

备注/Memo:
赵军(1988—),男,硕士学位,副主任医师。研究方向:中医骨伤、内分泌临床与基础研究。国家自然科学基金(30560165);国家中医药管理局中医药传承与创新“百千万人才工程”项目(J20184832009);第四批全国中医(临床、基础)优秀人才研修项目(J20184832009);内蒙古医科大学“科技百万工程”联合项目[YKD2017KJBW(LH)064];内蒙古自治区第三批老蒙医药中医药专家学术经验继承项目(内卫计蒙中字[2019]126);内蒙古自治区草原英才创新团队“中医治未病”项目(CYYCTD2018);内蒙古自治区自然科学基金(2009MS1134)。
更新日期/Last Update: 2022-07-15